The World Bank has been a strong supporter of MMV from its very inception in 1999. Since then, the Bank has provided MMV with annual financial support of $500,000 or $750,000 from 2000 through 2006, to the tune of $4,750,000.

In 2006 the Bank commissioned a Global Program Review (GPR) of MMV that was undertaken by the Independent Evaluation Group (IEG).

This recently-published review found MMV to be an effective program "that is efficiently managing a portfolio of candidates for new malaria drugs through the various phases of drug discovery and clinical development that precede formal registration with public authorities and marketing in the public and private sectors. MMV’s success in fundraising has permitted it to establish a strong pipeline of new malaria drugs that are expected to be affordable in developing countries. MMV’s decision to expand its activities to encompass facilitating the access and delivery of its malaria drugs raises new policy and institutional challenges for MMV as well as new opportunities for exploiting synergies with the World Bank’s country operations."

The Global Program Review considers MMV to be "a successful product development public private partnership (PD-PPP) in the field of malaria".